Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis

Arthritis and Rheumatism

Volumn 58, Issue 10, 2008, Pages 2993-2999

  Dass, Shouvik ^a   Rawstron, Andy C ^b   Vital, Edward M ^a   Henshaw, Karen ^a   McGonagle, Dennis ^a,c   Emery, Paul ^a,d  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^d CHAPEL ALLERTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; RITUXIMAB;

ARTICLE; B LYMPHOCYTE; CELL COUNT; CLINICAL ASSESSMENT; CYTOMETRY; EUROPEAN LEAGUE AGAINST RHEUMATISM; FLOW CYTOMETRY; HUMAN; INFUSION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; METHYLPREDNISOLONE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 54949129325     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23902     Document Type: Article

References (17)

1. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy [review]. Curr Dir Autoimmun 2005;8:140-74.
2. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
3. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schectman J, Szczepanski L, Kavanaugh A, et al, for the DANCER Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
4. Breedveld FC, Agarwal S, Yin M, Ng C, Li NF, Shaw TM, et al. Relationship between clinical response, rituximab pharmacokinetics and peripheral B cell levels in rheumatoid arthritis. Ann Rheum Dis 2006;65 Suppl II:ii179.
5. Rawstron AC, de Tute R, Jack AS, Hillmen P. Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens. Leukemia 2006;20:2102-10.
6. Rawstron AC, Villamor N, Ritgen M, Bottcher S, Ghia P, Zehnder JL, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007;21:956-64.
7. Rawstron AC, Kennedy B, Evans PA, Davies FE, Richards SJ, Haynes AP, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001;98:29-35.
8. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
9. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40.
10. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005;174:817-26.
11. Moreton P, Kennedy B, Lucas G, Leach M, Rassam SM, Haynes A, et al. Eradication of minimal residual disease in B cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005;23:2971-9.
12. Dass S, Burgoyne CH, Rawstron AC, Vital EM, Reece RJ, Ponchel F, et al. Reduction in synovial B cell levels after rituximab predicts response. Ann Rheum Dis 2007;66 Suppl II:ii90.
13. Vos K, Thurlings RM, Wijbrandts CA, Zwinderman A, van Schaardenburg D, Gerlag DM, et al. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:772-8.
14. Teng YK, Levarht EW, Hashemi M, Bajema IM, Toes RE, Huizinga TW, et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum 2007;56:3909-18.
15. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004;104:2635-42.
16. Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas D, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002;99:1038-43.
17. Popa C, Leandro M, Cambridge G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 2007;46:626-30.